Information Technology
Araceli Biosciences Closes $11.2M Seed Financing to Change the Pace of Drug Discovery
While advances in automation, genomics, and machine learning have transformed drug discovery, high-content imaging remains one of the slowest steps and a major bottleneck. Traditional imaging systems lack the speed and scalability required for modern AI-driven pipelines and multiplexed assays. Araceli addresses this critical gap with a platform purpose-built for speed, scale, and seamless AI integration—enabling researchers to generate more data, faster, with greater precision.
Proceeds from the Seed round will support:
"The future of AI-driven drug discovery and personalized medicine depends on imaging and analysis that happens in real time," said Matt Beaudet , CEO of Araceli Biosciences. "Minutes and seconds matter. The old model of waiting hours—or even days—for data is over. At Araceli, we're building a platform that moves at the speed of science."
Bill Cortelyou , Board Chairman and lead investor, added, "Araceli's breakthrough technology, experienced leadership, and clear market demand position the company well for significant growth potential."
Araceli Biosciences is a biotechnology company focused on accelerating drug discovery through innovations in high-content imaging and AI-driven analysis. With its flagship Endeavor® system and Clairvoyance software, Araceli empowers scientists to generate actionable insights faster and more efficiently across a wide range of biological applications.
Shawn MacDonald CFO, Araceli Biosciences
corporaterelations@aracelibio.com
https://www.aracelibio.com/Corporate-Relations
Logo - https://mma.prnewswire.com/media/2672131/Araceli_Biosciences_logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/araceli-biosciences-closes-11-2m-seed-financing-to-change-the-pace-of-drug-discovery-302436895.html